Reimagining the infrastructure of cancer care

When building a comparative effectiveness study or modeling long-term survival, health economics and outcomes research (HEOR) teams face a familiar problem: treatment pattern data derived from electronic health records (EHRs) tells you who the patient is clinically, and what happened, but historically not why.

Three-pillar framework sets methodological benchmark for data quality and transparency in oncology data

Broadens access to Abbott’s Precision Oncology tests across more than 1,600 community cancer care centers and 4,700 providers in Flatiron’s North America network, helping accelerate informed treatment decisions Allows oncologists to order tests and view results directly in the clinical workflow Abbott (NYSE: ABT), the global healthcare company, and Flatiron Health, a leading healthtech company advancing point-of-care solutions in oncology, today announced the integration of Abbott’s comprehensive Precision Oncology portfolio into OncoEMR®, Flatiron’s cloud-based Electronic Medical Record (EMR) platform. Through this integration, oncology providers can now digitally order Abbott tests – individually or in combination – and receive status updates and results directly within their existing OncoEMR clinical workflow. Available Abbott tests include the Oncotype DX Breast Recurrence Score®, OncoExTra®, Oncodetect®, and Riskguard® tests, enabling clinicians to access the comprehensive portfolio through a single, unified experience. This approach supports more informed treatment decisions across multiple stages of cancer care while helping reduce administrative burden and keeping the focus on patient care. The integration expands access to Abbott’s Precision Oncology tests across Flatiron’s national network of more than 1,600 community cancer care centers, where 4,700 providers deliver care and where most cancer care in the U.S. takes place. “We’re focused on making it easier for clinicians to access the right information at the right moment of care,” said Quincy Weatherspoon, VP and GM of Point of Care Solutions, Flatiron Health. “By integrating Abbott’s Precision Oncology portfolio directly into OncoEMR, we’re reducing friction in the workflow and helping providers move faster—from test ordering to treatment decisions. This is what it looks like to bring more connected, data-driven care to the point of care.” “For community oncology practices, where most cancer care is delivered, this removes a key barrier to accessing our portfolio at the point of care, helping accelerate treatment decisions and enabling more informed, personalized patient care,” said Brian Baranick, vice president, Precision Oncology, Abbott. About Abbott Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 122,000 colleagues serve people in more than 160 countries. Connect with us at abbott.com and on LinkedIn, Facebook, Instagram, X and YouTube. About Flatiron Flatiron Health is a healthtech company expanding the possibilities for point of care solutions in oncology and using data for good to power smarter care for every person with cancer. Through machine learning and AI, real-world evidence, and breakthroughs in clinical trials, we continue to transform patients’ real-life experiences into knowledge and create a more modern, connected oncology ecosystem. Flatiron Health is an independent affiliate of the Roche Group. Abbott Media Lisa Warshaw(323) 360-8778 Abbott Financial Michael Comilla(224) 668-1872 Flatiron Media Nina Toorpress@flatiron.com

The pace of progress in blood cancers is accelerating. Over the past decade, the FDA has approved dozens of targeted and immunotherapies, and breakthroughs like CAR T-cell therapy, bispecific antibodies, and MRD testing are transforming how these diseases are treated. What was once acute is increasingly becoming manageable, allowing many patients to live longer, more active lives. But progress only matters if patients can access it. As treatment options expand, clinical decision-making has become more complex. Clinicians must navigate evolving standards of care while accounting for disease biology, biomarkers, prior therapies, and individual patient considerations. At the same time, many advanced therapies remain concentrated in academic centers and can be difficult to access due to cost and geography - raising real questions about the gap in equity across patient populations. At Flatiron, we believe that gap is not inevitable. By generating high-quality, real-world evidence, we can help researchers address disparities and give clinicians the insights they need to make smarter, faster decisions across the patient journey. I recently joined leaders from Bristol Myers Squibb, Roche, and Incyte to discuss how real-world evidence is shaping the future of blood cancer research. You can watch the full webinar here. If you’re short on time, here are the four key insights I took away from the event.